COVID-19 in hematopoietic cell transplant recipients


Altuntas F. , Ata N., Yigenoglu T. N. , Bascı S., Dal M. S. , Korkmaz S., ...More

Bone Marrow Transplantation, vol.56, no.4, pp.952-955, 2021 (Journal Indexed in SCI Expanded) identifier identifier

  • Publication Type: Article / Letter
  • Volume: 56 Issue: 4
  • Publication Date: 2021
  • Doi Number: 10.1038/s41409-020-01084-x
  • Title of Journal : Bone Marrow Transplantation
  • Page Numbers: pp.952-955

Abstract

© 2020, The Author(s), under exclusive licence to Springer Nature Limited.In this study, we aim to report the outcome of COVID-19 in hematopoietic cell transplant (HCT) recipients. HCT recipients (n = 32) with hematological disease and hospitalized for COVID-19 were included in the study. A cohort of age and comorbid disease-matched hospitalized COVID-19 patients with hematological malignancy but not underwent HCT (n = 465), and another cohort of age and comorbid disease-matched hospitalized COVID-19 patients without cancer (n = 497) were also included in the study for comparison. Case fatality rate (CFR) was 5.6% in patients without cancer, 11.8 in patients with hematological malignancy and 15.6% in HCT recipients. The CFR in HCT recipients who were not receiving immunosuppressive agents at the time of COVID-19 diagnosis was 11.5%, whereas it was 33% in HCT recipients who were receiving an immunosuppressive agent at the time of COVID-19 diagnosis. In conclusion, our study reveals that for the current pandemic, HCT recipients, especially those receiving immunosuppressive drugs, constitute a special population of cancer patients.